Transcatheter heart valve (THV) is an umbrella term that refers to minimally invasive cardiac procedures that are performed using a small hollow tube (catheter) to either replace or repair one or more of the four heart valves. This can be done through a small hole in the leg or the chest wall. Transcatheter aortic valve implantation (TAVI) is the most commonly performed THV procedure in BC.
The provincial THV program was established in 2011 to capitalize on BC's pioneering accomplishments, support patients' access to innovative treatment options, and promote excellence of care. The objectives of the BC THV Program are to:
- promote evidence-based program development
- monitor quality of care
- coordinate timely access to treatment
- facilitate provincial excellence and leadership.
The current indications for TAVI in BC reflect the Canadian Cardiology Society guidelines, and include:
- severe symptomatic aortic stenosis
- higher risk for open heart surgery as documented by a BC surgeon
- heart team consensus of treatment decision
- likelihood to derive significant quantity and quality of life.
Technology, procedural approaches and scientific evidence are rapidly evolving. Multiple new generation devices are under development and clinical trials will inform future indications and changes in practice.
In collaboration with the heart teams at each site, we conduct an annual quality review to monitor adherence to indications, quality of care, and promote provincial excellence. The Cardiac Services BC-led approach to THV has resulted in excellent outcomes compared to data from other international registries.